Pulmonx stock.

Shares Outstanding 38.308M. Price to Book Ratio 3.23. Price to Sales Ratio 6.17. 1 Year Return 92.03%. 30 Day Avg Volume 249,701.83. EPS -1.62. About …Source: LSEG - data delayed by at least 15 minutes. Get Pulmonx Corp (LUNG.OQ) real-time stock quotes, news, price and financial information from Reuters …Feb 22, 2023 · Adjusted EBITDA loss in the fourth quarter of 2022 was $9.8 million compared to $9.4 million for the same period in 2021. Full Year 2022 Financial Results. Total worldwide revenue for the full year of 2022 was $53.7 million, an 11% increase from $48.4 million for the full year of 2021 and an increase of 16% on a constant currency basis. Adjusted EBITDA loss in the fourth quarter of 2022 was $9.8 million compared to $9.4 million for the same period in 2021. Full Year 2022 Financial Results. Total worldwide revenue for the full year of 2022 was $53.7 million, an 11% increase from $48.4 million for the full year of 2021 and an increase of 16% on a constant currency basis.

CVRx (NASDAQ:CVRX) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior stock?We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Daniel P. Florin has not been actively trading shares of Pulmonx within the last three months. Most recently, on Monday, July 12th, Daniel P. Florin bought 2,500 shares of Pulmonx stock. The stock was acquired at an average cost of $40.00 per share, with a total value of $100,000.00. Learn More on Daniel P. Florin's trading history.

Get the latest Pulmonx Corp (LUNG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Shares of Pulmonx stock opened at $10.85 on Tuesday. The company has a current ratio of 7.19, a quick ratio of 6.41 and a debt-to-equity ratio of 0.30. Pulmonx has a twelve month low of $5.15 and ...Pulmonx Corp [ LUNG] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director: 10% Owner: X: Officer (give title below) ... Common Stock: 11/22/2023: S (1) 1,184: D $ 10.6: 249,469: D: Table II - Derivative Securities Acquired, Disposed of, or Beneficially OwnedNov 15, 2023 · REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference in New York on Wednesday, November 29, 2023, at 11:00 AM PT / 2:00 PM ET. Feb 23, 2022 · REDWOOD CITY, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2021 ended December 31, 2021.

Dec 1, 2023 · According to 7 stock analysts, the average 12-month stock price forecast for Pulmonx stock is $13.71, which predicts an increase of 22.08%. The lowest target is $8.00 and the highest is $18. On average, analysts rate Pulmonx stock as a buy.

View the latest Pulmonx Corp. (LUNG) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Pulmonx Corporation is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.Oct 23, 2023 · Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing. 0001950047-23-004593.pdf. 0001950047-23-004593.rtf. 0001950047-23-004593.xls. View HTML. Oct 19, 2023. 3. Initial filing by director officer or owner of more than ten percent. Stock split history for Pulmonx since 2020. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values. Compare LUNG With Other Stocks Pulmonx Annual Stock Splits; Pulmonx Quarterly Stock Splits; Sector IndustryFeb 24, 2023 · Shares of Pulmonx Corporation (LUNG-0.09%) ... The stock closed last week at $9.23 and rose to as high as $12.38 on Thursday. Overall, it is down more than 58% over the past 12 months but is up ... Nov 8, 2023 · Verdict: Pulmonx Corporation lost a $1.59 a share on just over $53.6 million of revenue in FY2022. The current analyst firm consensus has losses increasing to $1.71 a share in FY2023 even as sales ... Pulmonx continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based ...The stock of Pulmonx Corp (LUNG) has seen a -2.31% decrease in the past week, with a 18.89% gain in the past month, and a 5.63% flourish in the past quarter. The volatility ratio for the week is 5.66%, and the volatility levels for the past 30 days are at 5.40% for LUNG. The simple […]

Pulmonx also continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock ...Oct 30, 2023 · Pulmonx is increasing its expectation for revenue in 2023 to now range from $67 million to $68 million, which represents approximately 25% to 27% growth over the Company's fiscal year 2022 revenue. This updated guidance compares to prior 2023 revenue guidance of $64 million to $66 million. The Company expects gross margin for the full year 2023 ... Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Improved health status. Improved lung function. Increased exercise capacity. Reduced breathlessness or dyspnea. Reduced gas trapping. Improved quality of life. GOLD’s evidence “A” rating affirms that endobronchial valves, like the Zephyr ® Valve, are a viable, minimally–invasive treatment option for severe emphysema, a form of COPD. 10.Jul 2, 2022 · The stock opened at $40 on day 1, and soon galloped to almost $70 a share (Figure 5). However, Pulmonx, along with other speculative equities, soon cooled off. From the peak in January 2021, LUNG ... The Pulmonx Corporation stock price fell by -0.0906% on the last day (Wednesday, 29th Nov 2023) from $11.04 to $11.03. During the last trading day the stock fluctuated 4.37% from a day low at $10.99 to a day high of $11.47. The price has risen in 5 of the last 10 days and is up by 0.46% over the past 2 weeks.The U.S. market, in particular, has been a major contributor to Pulmonx’s growth, with $11.8 million in sales in the third quarter, representing a substantial 41% year-over-year growth (Q3 2023).

The stock of Pulmonx Corp (LUNG) has seen a -2.31% decrease in the past week, with a 18.89% gain in the past month, and a 5.63% flourish in the past quarter. The volatility ratio for the week is 5.66%, and the volatility levels for the past 30 days are at 5.40% for LUNG. The simple […]

Stock split history for Pulmonx since 2020. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values. Compare LUNG With Other Stocks Pulmonx Annual Stock Splits; Pulmonx Quarterly Stock Splits; Sector IndustryA Brief History of Pulmonx Corporation (LUNG) Pulmonx Corporation is a medical device company that focuses on providing minimally invasive solutions for patients with severe emphysema. The company was founded in 1998 and is based in Redwood City, California. 1998: Pulmonx Corporation was founded with the goal of developing innovative …Nov 17, 2023 · The U.S. market, in particular, has been a major contributor to Pulmonx’s growth, with $11.8 million in sales in the third quarter, representing a substantial 41% year-over-year growth (Q3 2023). Get the latest Pulmonx Corp (LUNG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Pulmonx (NASDAQ: LUNG) attributes ... Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth ...Oct 30, 2023 · Corporate Overview. Pulmonx Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who, despite medical management, are still profoundly symptomatic. Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.A rating of 77 puts Pulmonx Corp near the top of the Medical Devices industry according to InvestorsObserver. Pulmonx Corp's score of 77 means it scores higher than 77% of stocks in the industry. Pulmonx Corp also received an overall rating of 54, putting it above 54% of all stocks. Medical Devices is ranked 82 out of the 148 industries.

Oct 30, 2023 · Pulmonx is increasing its expectation for revenue in 2023 to now range from $67 million to $68 million, which represents approximately 25% to 27% growth over the Company's fiscal year 2022 revenue. This updated guidance compares to prior 2023 revenue guidance of $64 million to $66 million. The Company expects gross margin for the full year 2023 ...

The U.S. market, in particular, has been a major contributor to Pulmonx’s growth, with $11.8 million in sales in the third quarter, representing a substantial 41% year-over-year growth (Q3 2023).

Get the latest news and real-time alerts from Pulmonx Corporation (LUNG) stock at Seeking Alpha. 10 octombrie 2023. iO Charts is a Seeking Alpha partner. Pulmonx Corporation (LUNG) Q2 2023 Earnings Call Transcript. Pulmonx Corporation (NASDAQ:NASDAQ:LUNG) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM …Oct 30, 2023 4:30 PM EDT. Pulmonx Q3 2023 Earnings Conference Call. Listen to webcast. Sep 6, 2023 2:15 PM EDT. 2023 Wells Fargo Healthcare Conference. Listen to webcast. Aug 9, 2023 12:00 PM PDT. Canaccord Genuity 43rd Annual Growth Conference. Listen to webcast.8.99. +0.30. +3.45%. Get Pulmonx Corp (LUNG:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.According to the issued ratings of 7 analysts in the last year, the consensus rating for Pulmonx stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 5 buy ratings for LUNG. The average twelve-month price prediction for Pulmonx is $13.29 with a high price target of $18.00 and a low price target of $8.00.REDWOOD CITY, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Sep. 4, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International …Pulmonx, a US-based developer of minimally invasive lung disease treatments, has unveiled positive interim results for its AeriSeal System, from the CONVERT Study. CONVERT is an open-label, multi-centre, single-arm study, planned to enrol 140 subjects with severe emphysema and collateral ventilation in the target lobe, at up to 20 …We would like to show you a description here but the site won’t allow us.Check out our LUNG stock chart to see a history of performance, current stock value, ... Pulmonx Corp Ordinary Shares LUNG. Morningstar Rating Unlock. Stock XNAS Rating as of Oct 31, 2023.Short interest for Pulmonx gives investors a sense of the degree to which investors are betting on the decline of Pulmonx's stock. Short interest data is updated every two weeks.October 25, 2023. $8.40. 266,866. 1:1. $8.58. $8.73. $8.27. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.May 2, 2023 · Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.33% and 6.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corp Current Ratio is currently at 11.85 X. Current Ratio is calculated by dividing the Current Assets of Pulmonx Corp by its Current Liabilities. It measures whether or not Pulmonx Corp has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for Pulmonx.Positive. Nikkei 225. 31,650.96. -1.97%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Pulmonx Corp (LUNG.OQ) real-time stock quotes, news, price and financial information from ...Pulmonx General Information. Description. Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary …Shares of Pulmonx Corporation (LUNG-0.09%) ... The stock closed last week at $9.23 and rose to as high as $12.38 on Thursday. Overall, it is down more than 58% over the past 12 months but is up ...Instagram:https://instagram. upside app reviews 2023gsy etfwhere can i buy lunatempurpedic stock Pulmonx Corp Total Asset. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.Pulmonx Corp Stock Price History. Pulmonx Corp’s price is currently up 13.99% so far this month. During the month of November, Pulmonx Corp’s stock price has reached a high of $10.10 and a low of $8.60. Over the last year, Pulmonx Corp has hit prices as high as $14.28 and as low as $5.13. Year to date, Pulmonx Corp’s stock is down 68.76%. best books to learn day tradingbest emerging markets etfs Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.33% and 6.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? how much is a standard gold bar worth The all-time high Pulmonx stock closing price was 69.02 on December 31, 2020 . The Pulmonx 52-week high stock price is 45.49 , which is 268.6% above the current share price. The Pulmonx 52-week low stock price is 12.23 , which is 0.9% below the current share price. The average Pulmonx stock price for the last 52 weeks is 22.86 . For more ...Pulmonx Co. (NASDAQ:LUNG – Get Rating) saw unusually large options trading activity on Tuesday. Investors purchased 5,956 call options on the company. This represents an increase of 3,265% compared to the average volume of 177 call options. Hedge Funds Weigh In On Pulmonx Several large investors have recently modified their …Complete Pulmonx Corp. stock information by Barron's. View real-time LUNG stock price and news, along with industry-best analysis.